中华内科杂志
中華內科雜誌
중화내과잡지
CHINESE JOURNAL OF INTERNAL MEDICINE
2009年
5期
392-395
,共4页
吴涛%白海%王存邦%张茜%澹台林芳%王晓靖%欧建锋%赵强
吳濤%白海%王存邦%張茜%澹檯林芳%王曉靖%歐建鋒%趙彊
오도%백해%왕존방%장천%담태림방%왕효정%구건봉%조강
骨髓%间质干细胞%造血干细胞
骨髓%間質榦細胞%造血榦細胞
골수%간질간세포%조혈간세포
Bone marrow%Mesenchymal stem cells%Hematopoietic stem cells
目的 研究自体骨髓间充质干细胞(MSCs)与造血干细胞共移植治疗恶性血液病的安全性和可行性,及其对移植后造血重建的影响.方法 从无骨髓浸润的恶性血液病患者本人骨髓中分离、培养间充质干细胞,经放化疗等预处理后,与造血干细胞共移植治疗恶性血液病患者5例,其中恶性淋巴瘤4例,粒细胞肉瘤1例,并观察其对移植后造血重建的影响.结果 MSCs联合造血干细胞共移植治疗恶性血液病患者5例,MSCs输注过程顺利,未见明显不良反应.移植后造血恢复过程中,中性粒细胞≥0.5×109/L的中位时间为9.4(8~11)d、血小板≥20×109/L的中位时间为12.2(10~14)d.结论 MSCs联合造血干细胞共移植治疗恶性血液病安全性好,未见明显副作用.结果 提示输注MSCs可促进造血恢复,但其远期疗效仍有待于进一步观察.
目的 研究自體骨髓間充質榦細胞(MSCs)與造血榦細胞共移植治療噁性血液病的安全性和可行性,及其對移植後造血重建的影響.方法 從無骨髓浸潤的噁性血液病患者本人骨髓中分離、培養間充質榦細胞,經放化療等預處理後,與造血榦細胞共移植治療噁性血液病患者5例,其中噁性淋巴瘤4例,粒細胞肉瘤1例,併觀察其對移植後造血重建的影響.結果 MSCs聯閤造血榦細胞共移植治療噁性血液病患者5例,MSCs輸註過程順利,未見明顯不良反應.移植後造血恢複過程中,中性粒細胞≥0.5×109/L的中位時間為9.4(8~11)d、血小闆≥20×109/L的中位時間為12.2(10~14)d.結論 MSCs聯閤造血榦細胞共移植治療噁性血液病安全性好,未見明顯副作用.結果 提示輸註MSCs可促進造血恢複,但其遠期療效仍有待于進一步觀察.
목적 연구자체골수간충질간세포(MSCs)여조혈간세포공이식치료악성혈액병적안전성화가행성,급기대이식후조혈중건적영향.방법 종무골수침윤적악성혈액병환자본인골수중분리、배양간충질간세포,경방화료등예처리후,여조혈간세포공이식치료악성혈액병환자5례,기중악성림파류4례,립세포육류1례,병관찰기대이식후조혈중건적영향.결과 MSCs연합조혈간세포공이식치료악성혈액병환자5례,MSCs수주과정순리,미견명현불량반응.이식후조혈회복과정중,중성립세포≥0.5×109/L적중위시간위9.4(8~11)d、혈소판≥20×109/L적중위시간위12.2(10~14)d.결론 MSCs연합조혈간세포공이식치료악성혈액병안전성호,미견명현부작용.결과 제시수주MSCs가촉진조혈회복,단기원기료효잉유대우진일보관찰.
Objective To explore the feasibility and safety of cotransplantation of autologous bone marrow-derived mesenehymal stem cells (MSCs) and peripheral blood stem cells in hematological malignant diseases and to observe its effect on hematopoietic reconstruction after cotransplantation. Methods Adult human MSCs were isolated from the healthy bone marrow of the patient himself with Percoll (1. 073 g/ml) and cultured in Dulbecco's modified Eagle's medium with low glucose containing 10% AB type human serum. After conditioning regimen of high-dose chemotherapy and radiotherapy, cotransplantation of autologous bone marrow-derived MSCs and peripheral blood stem cells was done in five patients with hematological malignant diseases. Results The process of the infusion was safe and there were no adverse reactions or other toxicities related to the infustion of MSCs. The median time to achieve neutrophil counts greater than 0. 5 × 109/L was 9.4 days ( ranging from 8 to 11 days) after cotransplantation and platelet counts greater than 20 × 109/L 12. 2 days (ranging from 10 to 14 days). Conclusion Cotransplantation of autologous bone marrow-derived MSCs and peripheral blood stem cells in hematological malignant diseases is feasible and safe. The rapid hematopoietic reconstruction after cotransplantation shows that MSCs have an effect on hematopeiesis, but the mechanism is still to be investigated.